Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer-cohort B
| Title | Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer-cohort B |
|---|---|
| Description | Previous small size studies reported BRAF mutated NSCLC patients have comparable sensitivity to immune checkpoint inhibitors (ICIs). However, how BRAF mutation affects the tumor immune microenvironment (TIME) of NSCLC is unknown. We performed Nanostring-panel RNA sequencing to evaluate TIME in 57 BRAF mutated and wild-type (WT) NSCLC specimens (cohort A). The efficacy of ICI monotherapy or combined therapies was determined in 417 patients with WT and BRAF mutated NSCLC (cohort B). |
| Organism | Homo sapiens |
| Data Type | Clinical Research data |
| Data Accessibility | Open-access |
| BioProject | PRJCA011037 |
| Release Date | 2022-08-09 |
| Submitter | Hui Li (11118029@zju.edu.cn) |
| Organization | Zhejiang Cancer Hospital |
| Submission Date | 2022-08-07 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX001549-01 | survival data for cohort B | 417 | Clinical Research data | 952.0 KB | zip | 0 |